Press Release Nicox Restructures Kreos Capital Bond Financing Agreement and Raises €15 Million in Private Placement Net proceeds from the private placement together with the restructuring
Press ReleaseNicox's Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease A subgroup of patients in the Phase 2b Mississippi clinical trial
Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update
Lead value drivers are 100% ownership of NCX 470 and NCX 4251 in the U.S
.
21
C
sufficient for the Company to
meet its current requirements for the next twelve months July 16, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, provided business and financial highlights for Q2 2021 for Nicox SA and its subsidiaries (the Nicox Group ) as well as an update on its strategy and key expected value-inflection milestones today.
timely
NCX 4251
etain the full revenue poten
tial from
in the U.S.
and
for future
value as we continue the development of our clinical assets NCX 470 in glaucoma and NCX 4251 in blepharitis.”
Latanoprostene bunod, the pharmaceutical active ingredient in VYZULTA, was invented and patented by Nicox, and is the first product from the company’s proprietary nitric oxide-donating research platform to be approved for commercialization. Under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the “Hatch-Waxman Act”) certain patents for pharmaceutical products in the U.S. may be extended by up to 5 years once product approval from the FDA has been obtained.
Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021 January 29, 2021 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its bond financing agreement with Kreos Capital, introducing an additional one-year period of interest-only payments on the outstanding principal starting on February 1, 2021, and an extension of the overall period of the loan by 6 months to July 2024. The new one-year interest-only period is expected to provide approximately €5.5 million of additional flexibility for investment in development activities in 2021. The interest rate of the bonds remains unchanged as a result of this amendment. Nicox has granted Kreos Capital 100,000 warrants for 100,000 Nicox shares, equivalent to approximately 0.27% of the present outstanding capital of the Company.